Michael David Garrison Sells 1,610 Shares of Becton, Dickinson and Company (NYSE:BDX) Stock

Becton, Dickinson and Company (NYSE:BDX) EVP Michael David Garrison sold 1,610 shares of the business’s stock in a transaction that occurred on Thursday, January 15th. The shares were sold at an average price of $207.46, for a total transaction of $334,010.60. Following the sale, the executive vice president owned 12,095 shares in the company, valued at $2,509,228.70. This represents a 11.75% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Michael David Garrison also recently made the following trade(s):

• On Wednesday, December 17th, Michael David Garrison sold 629 shares of Becton, Dickinson and Company stock. The shares were sold at an average price of $196.03, for a total value of $123,302.87.

Becton, Dickinson and Company Trading Down 0.6%

Shares of NYSE:BDX opened at $207.16 on Friday. Becton, Dickinson and Company has a 12-month low of $162.29 and a 12-month high of $251.99. The company has a quick ratio of 0.64, a current ratio of 1.11 and a debt-to-equity ratio of 0.69. The firm has a market capitalization of $59.02 billion, a P/E ratio of 35.53, a price-to-earnings-growth ratio of 2.29 and a beta of 0.23. The firm has a fifty day moving average of $195.88 and a two-hundred day moving average of $189.39.

Becton, Dickinson and Company (NYSE:BDX) last posted its earnings results on Thursday, November 6th. The medical instruments supplier reported $3.96 earnings per share for the quarter, beating the consensus estimate of $3.92 by $0.04. Becton, Dickinson and Company had a return on equity of 16.42% and a net margin of 7.68%.The company had revenue of $5.89 billion for the quarter, compared to analyst estimates of $5.91 billion. During the same period last year, the company earned $3.81 earnings per share. The business’s revenue was up 8.3% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 14.750-15.050 EPS. On average, equities analysts expect that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, December 31st. Stockholders of record on Monday, December 8th were issued a dividend of $1.05 per share. This represents a $4.20 annualized dividend and a dividend yield of 2.0%. The ex-dividend date of this dividend was Monday, December 8th. This is a boost from Becton, Dickinson and Company’s previous quarterly dividend of $1.04. Becton, Dickinson and Company’s payout ratio is 72.04%.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on BDX shares. Wall Street Zen lowered Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research note on Saturday, November 8th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Becton, Dickinson and Company in a research note on Wednesday, October 8th. Piper Sandler cut their price objective on Becton, Dickinson and Company from $200.00 to $190.00 and set a “neutral” rating for the company in a report on Friday, November 7th. Jefferies Financial Group increased their target price on shares of Becton, Dickinson and Company from $215.00 to $220.00 and gave the stock a “buy” rating in a research report on Wednesday, December 10th. Finally, Stifel Nicolaus lifted their price target on shares of Becton, Dickinson and Company from $210.00 to $215.00 and gave the company a “buy” rating in a report on Wednesday, January 7th. Four equities research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $207.64.

Institutional Trading of Becton, Dickinson and Company

Several hedge funds have recently added to or reduced their stakes in BDX. Perigon Wealth Management LLC increased its holdings in shares of Becton, Dickinson and Company by 4.0% in the fourth quarter. Perigon Wealth Management LLC now owns 2,492 shares of the medical instruments supplier’s stock worth $484,000 after acquiring an additional 95 shares in the last quarter. Dorato Capital Management acquired a new position in shares of Becton, Dickinson and Company in the 4th quarter valued at approximately $635,000. Earned Wealth Advisors LLC bought a new stake in Becton, Dickinson and Company during the 4th quarter worth approximately $205,000. HF Advisory Group LLC raised its holdings in Becton, Dickinson and Company by 559.3% during the 4th quarter. HF Advisory Group LLC now owns 34,230 shares of the medical instruments supplier’s stock worth $6,643,000 after buying an additional 29,038 shares during the period. Finally, Legacy Capital Wealth Partners LLC lifted its stake in Becton, Dickinson and Company by 18.3% in the fourth quarter. Legacy Capital Wealth Partners LLC now owns 2,542 shares of the medical instruments supplier’s stock valued at $493,000 after buying an additional 394 shares in the last quarter. Institutional investors and hedge funds own 86.97% of the company’s stock.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.